Article

Ropes & Gray Attorneys Discuss the Intersection of the Lanham Act and the Federal Food, Drug, and Cosmetic Act in Bloomberg BNA’s Pharmaceutical Law & Industry Report


Time to Read: 1 minutes Practices: Intellectual Property Litigation, Life Sciences

In an April 18 article published in Bloomberg BNA’s Pharmaceutical Law & Industry Report, intellectual property litigation partner Peter Brody (Washington, D.C.) discusses the overlap between the Lanham Act and the Federal Food, Drug, and Cosmetic Act. The article, titled “Preclusion, Primary Jurisdiction, and Private Enforcement: The Intersection of the Lanham Act and the Federal Food, Drug, and Cosmetic Act,” provides a framework for greater consistency in the litigation and adjudication of false advertising cases that fall between these statutes.

Cookie Settings